J.W. Cole Advisors’s TG Therapeutics TGTX Stock Holding History

J.W. Cole Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,803	Closed	-$370K	–	996
2024 Q3	$370K	Buy	15,803 +103	+0.7%	+$2.25K	0.02%	707
2024 Q2	$279K	Sell	15,700 -3,659	-19%	-$58.4K	0.01%	727
2024 Q1	$294K	Buy	19,359 +700	+4%	+$11.2K	0.01%	698
2023 Q4	$319K	Hold	18,659	–	–	0.02%	628
2023 Q3	$156K	Hold	18,659	–	–	0.01%	696
2023 Q2	$463K	Hold	18,659	–	–	0.03%	447
2023 Q1	$281K	Buy	18,659 +3,659	+24%	+$55.6K	0.02%	623
2022 Q4	$177K	Hold	15,000	–	–	0.01%	698
2022 Q3	$89K	Hold	15,000	–	–	0.01%	698
2022 Q2	$64K	Hold	15,000	–	–	0.01%	712
2022 Q1	$143K	Hold	15,000	–	–	0.01%	769
2021 Q4	$285K	Hold	15,000	–	–	0.02%	670
2021 Q3	$499K	Buy	+15,000	New	+$464K	0.04%	262

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

J.W. Cole Advisors's TGTX Position: Q4 2024 in Review

J.W. Cole Advisors sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 15,803 shares — an estimated $370K sold.

J.W. Cole Advisors first reported a position in TGTX in Q3 2021 and held it in 13 quarters. The position peaked at $499K in Q3 2021. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

J.W. Cole Advisors reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
J.W. Cole Advisors sold 15,803 TG Therapeutics shares in Q4 2024, an estimated $370K.
J.W. Cole Advisors first reported a position in TG Therapeutics in Q3 2021 and held it in 13 quarters.
J.W. Cole Advisors's TG Therapeutics position peaked at $499K in Q3 2021.
331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on J.W. Cole Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.